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BACKGROUND: The Toll-like receptor (TLR) 4 signalling pathway has been shown to have oncogenic effects in vitro and in vivo.T o
demonstrate the role of TLR4 signalling in colon tumourigenesis, we examined the expression of TLR4 and myeloid differentiation
factor 88 (MyD88) in colorectal cancer (CRC).
METHODS: The expression of TLR4 and MyD88 in 108 CRC samples, 15 adenomas, and 15 normal mucosae was evaluated by
immunohistochemistry, and the correlations between their immunoscores and clinicopathological variables, including disease-free
survival (DFS) and overall survival (OS), were analysed.
RESULTS: Compared with normal mucosae and adenomas, 20% cancers displayed high expression of TLR4, and 23% cancers showed
high expression of MyD88. The high expression of TLR4 and MyD88 was significantly correlated with liver metastasis (P¼0.0001,
P¼0.0054). In univariate analysis, the high expression of TLR4 was significantly associated with shorter OS (hazard ratio (HR): 2.17;
95% confidence interval (95% CI): 1.15–4.07; P¼0.015). The high expression of MyD88 expression was significantly associated with
poor DFS and OS (HR: 2.33; 95% CI: 1.31–4.13; P¼0.0038 and HR: 3.03; 95% CI: 1.67–5.48; P¼0.0002). The high combined
expression of TLR4 and MyD88 was also significantly associated with poor DFS and OS (HR: 2.25; 95% CI: 1.27–3.99; P¼0.0053
and HR: 2.97; 95% CI: 1.64–5.38; P¼0.0003). Multivariate analysis showed that high expressions of TLR4 (OS: adjusted HR: 1.88;
95% CI: 0.99–3.55; P¼0.0298) and MyD88 (DFS: adjusted HR: 1.93; 95% CI: 1.01–3.67; P¼0.0441; OS: adjusted HR: 2.25; 95% CI:
1.17–4.33; P¼0.0112) were independent prognostic factors of OS. Furthermore, high co-expression of TLR4/MyD88 was strongly
associated with both poor DFS and OS.
CONCLUSION: Our findings suggest that high expression of TLR4 and MyD88 is associated with liver metastasis and is an independent
predictor of poor prognosis in patients with CRC.
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Colorectal cancer (CRC) is the fourth leading cause of cancer-
related death in the world and the third leading cause in the United
States (Jemal et al, 2009). In Japan, the incidence of CRC has
doubled over the past 20 years, and it was the second leading cause
of cancer-related death during that period (Tsukuma et al, 2004).
Although recent advances in chemotherapy have prolonged the
survival of patients with advanced disease, the results are still
unsatisfactory, and further research is required to understand the
disease and improve its outcome (Wolpin et al, 2007; Wolpin and
Mayer, 2008).
Toll-like receptors (TLRs) expressed on immune cells have a
critical role in immune responses against invading pathogens
(Akira et al, 2006). At least 11 mammalian TLRs have been
identified and are involved in recognition by immune and non-
immune cells of pathogen-associated molecular patterns, such as
lipopolysaccharides (LPSs), viral double-stranded RNA, and
unmethylated CpG islands (Akira et al, 2006). The TLRs transmit
signals through one or more of four adaptor proteins, namely,
Received 20 November 2009; revised 6 January 2010; accepted 8 January
2010; published online 9 February 2010
*Correspondence: Dr ZR Qian, Department of Human Pathology, The
University of Tokushima School of Medicine, 3-18-15 Kuramoto-cho,
Tokushima 770-8503, Japan; E-mail: zrqian@basic.med.tokushima-u.ac.jp
8These authors contributed equally to this work.
British Journal of Cancer (2010) 102, 908–915
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smyeloid differentiation factor 88 (MyD88), MyD88 adaptor-like,
Toll/IL1R domain-containing adaptor molecule inducing interfer-
on-b, and TRIF-related adaptor molecule (Rakoff-Nahoum and
Medzhitov, 2009). Stimulation of TLR leads to the activation of
nuclear factor-kB (NF-kB) and mitogen-activated protein kinases,
which are essential for the classical outcomes of TLR activation:
host innate and adaptive immune responses (Rakoff-Nahoum and
Medzhitov, 2009). Toll-like receptor-mediated activation of innate
or adaptive immunity may be used as an effective immuno-
adjuvant in tumour immunotherapy or combined tumour therapy
(Huang et al, 2008; Rakoff-Nahoum and Medzhitov, 2009).
However, recent evidence has shown that functional TLRs are
expressed on a wide variety of tumours (Huang et al, 2008; Rakoff-
Nahoum and Medzhitov, 2009). Contemporary experimental
evidence suggests that TLRs have important roles in tumouri-
genesis (Killeen et al, 2008). Lipopolysaccharide, a putative ligand
for TLR4, may promote tumour progression by acting directly on
cancer cells, resulting in increased tumour cell–endothelial cell
adhesion, tumour cell–extracellular matrix adhesion, and tumour
cell–extracellular matrix invasion through NF-kB-mediated upre-
gulation of b-1 integrin (Andrews et al, 2001; Wang et al, 2003).
Helicobacter pylori acting through TLR2/TLR9 on gastric epithelial
cells activated both Src and NF-kB, resulting in an increased
expression of cyclooxygenase-2 (Cox-2), which may contribute to
gastric cancer progression (Chang et al, 2004). The triggering of
TLR4 and TLR9 on prostate cancer cells has also been shown to
promote tumour cell proliferation through increased NF-kB
activation (Kundu et al, 2008).
Mounting evidence suggests that innate immune responses
to luminal microbes participate in the development of gastro-
intestinal malignancies (Fukata and Abreu, 2008). The large
intestine contains the highest density of microorganisms with
the potential to have a key function in colorectal carcinogenesis
(Fukata and Abreu, 2008). An expanding body of experimental
studies has identified the contribution of TLR signalling to intestinal
carcinogenesis (Fukata and Abreu, 2008). Blocking TLR4 signalling
in colon cancer cells resulted in the reduction of tumour growth in
a subcutaneously implanted mouse model (Huang et al, 2005). In
addition, the involvement of TLR signalling through MyD88 in
tumour growth and progression has been demonstrated in an
Apc
min/þ mice model (Rakoff-Nahoum and Medzhitov, 2007).
Furthermore, a recent study reported that TLR4 activation seems
to promote the development of colitis-associated cancer by
enhancing Cox-2 expression and increasing epidermal growth
factor receptor (EGFR) signalling (Fukata et al, 2007). These
findings have opened a multitude of oncological therapeutic
opportunities. However, little is known about the clinical signifi-
cance of TLR-4/MyD88 signalling expression in sporadic CRC.
In this study, we performed a systematic immunohistochemical
analysis of TLR4 and MyD88 expression in normal colon mucosae,
adenomas, and CRC. The analysis of the investigation involved two
parts: The first was concerned with the correlation between
pathological factors and protein expression, and the second tested
the correlation between protein expression and disease-free
survival (DFS) and overall survival (OS).
MATERIALS AND METHODS
Patients and human tissues
A total of 108 patients with CRC (62 males and 46 females) who
underwent surgery from 1990 to 1999 at the Tokushima University
Hospital were investigated in this study. Information on patient
demographics (sex and age) and tumour features (anatomical site,
histology, vascular invasion, lymphatic invasion, lymph node
metastasis, liver metastasis, peritoneal metastasis, and TNM stage)
was obtained from clinical and pathological records (Table 1). The
tumour site was classified as proximal or distal with respect to the
splenic flexure. Disease stages were classified according to the
criteria proposed by the Standard AJCC (American Joint
Committee on Cancer) (Fleming et al, 1997). Disease-free survival
was defined as the interval between the day that surgery was
performed and the day that recurrence was first detected. If
recurrence was not diagnosed, the date of death or of last follow-up
was used. Overall survival was defined as the interval between the
dates of surgery and death. The follow-up period after the initial
operation for the primary lesion was 5 years for DFS and OS.
Exclusion criteria were cancers associated with ulcerative colitis,
Crohn’s disease, or familial adenomatous polyposis. Ethical
approval for the project was obtained from the Tokushima
University Hospital Research Ethics Committee.
For the immunohistochemical study, formalin-fixed, paraffin-
embedded tissue samples from 15 normal mucosa tissues obtained
by colon biopsy, as well as 15 adenomas, 108 CRC, and 14 liver
metastases, were used.
Immunohistochemistry for TLR4 and MyD88
To immunostain TLR4 and MyD88 proteins, the streptavidin–
biotin labelling method was carried out on 4mm tissue sections as
described previously (Rahman et al, 2009). After deparaffinisation
in xylene and rehydration in a series of ethanols, the sections were
then treated with 0.3% hydrogen peroxide to block endogenous
peroxidase activity for 30min. Antigen retrieval was performed
using an autoclave oven technique. The tissue sections were then
incubated with a serum-free protein blocker and incubated at 41C
overnight with mouse monoclonal anti-human TLR4 antibody
(1:100; HTA125, eBioscience, San Diego, CA, USA) or rabbit
polyclonal anti-MyD88 antibody (1:100; HFL-296, Santa Cruz
Biotech, Santa Cruz, CA, USA). The biotinylated secondary
antibody and peroxidase-labelled streptavidin (DakoCytomation,
Glostrup, Denmark) were applied for 50min each at room
temperature. Antigen–antibody complexes were visualised using
the 3, 30-diaminobenzidine reaction. For confirmation, the
3-amino-9-ethylcarbazole reaction was also used. The slides were
counterstained lightly with haematoxylin and mounted for
microscopic examination. Human tonsil tissue was used as a
positive control for TLR4 and MyD88 immunoreactivity. Phos-
phate-buffered saline without the primary antibody served as a
negative control.
Evaluation of immunohistochemical findings
Each slide was evaluated independently by two pathologists who
were blinded to clinical and outcome data. As most samples
stained for TLR4 and MyD88 showed similar colour intensity,
from moderate to strong, no evaluation of colour intensity was
performed in this study. Any intensity of membrane and/or
cytoplasmic staining was considered to represent a positive stain
for TLR4 and MyD88. Several high-power fields ( 200) selected
from different staining density regions including high, moderate,
low, and negative staining areas were captured using a digital
camera (Olympus Q-color 3; Olympus Inc., Center Valley, PA,
USA). Photographs were printed on plain paper and a grid was
drawn over them. We counted a mean of 2000 tumour cells per
tumour (range, 1500–2500), and the results were expressed as the
percentage of tumour cells with a positive stain. Thereafter, the
percentage of TLR4- or MyD88-positive tumour cells was scored
on a scale of 0–4 (0: no staining; 1þ: p10%; 2þ: 11–30%; 3þ:
31–50%; 4þ: 450%). Furthermore, the expression levels of TLR4
and MyD88 were divided into the following two groups according
to score: low (0, 1þ,2 þ) and high (3þ,4 þ). In addition, the
sum of the score of TLR4/MyD88 staining was divided into the
following two groups: o5 and X5.
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Analysis was performed using StatView J-4.5 software (Abacus
Concepts, Berkeley, CA, USA). The Pearson w
2 test or Fisher’s exact
test was used to compare qualitative variables. The primary statistical
outcomes were DES and OS measured from the day of surgery. Both
DFS and OS were estimated by Kaplan–Meier curves, and the curves
were compared using the log-rank test. Time to relapse and to death
was analysed using the Cox proportional hazards model for
univariate and multivariate analyses. In addition, the hazard ratios
(HRs) between prognostic groups and their 95% confidence intervals
were computed. Probability values (P) o0.05 were considered to be
statistically significant.
RESULTS
TLR4 and MyD88 expression in normal colonic mucosae,
adenomas, and cancers
Immunolocalisation of TLR4 protein was observed in the
membrane and cytoplasm. In general, TLR4 expression was absent
or very weak in the normal mucosae collected from biopsy samples
and cancer margin samples (Figure 1A). This finding is consistent
with those of earlier reports (Cario and Podolsky, 2000; Furrie
et al, 2005; Fukata and Abreu, 2008). The expression of TLR4 was
also absent or weak in adenomas (Figure 1A). Compared with
normal mucosae and adenomas, the expression of TLR4 was
detected in a high proportion of cancers (78 of 108, 72%)
(Figure 1B). A total of 22 cancers displayed high expression (4þ:
6, 3þ: 16), and 86 cancers showed low expression (2þ: 33, 1þ:
23 and 0: 30) (Table 1). Among the 14 liver metastases obtained by
hepatectomy, 12 (86%) were TLR4 positive and 6 (43%) showed a
high expression.
Immunolocalisation of MyD88 protein was observed in the
cytoplasm. Similar to that of TLR4, MyD88 expression was absent
or very weak in normal mucosae, cancer margin samples, and
adenomas (Figure 1A). In CRC, a total of 93 of 108 (86%) cancers
showed MyD88 expression (Figure 1C). A high-level expression
was detected in 25 cancers (23%) (4þ: 10, 3þ: 15). In all, 83
cancers showed a low-level expression (2þ: 33, 1þ: 35, and 0: 15).
All of 14 liver metastases were positive for MyD88 expression and
12 (86%) of them displayed high expression.
Table 1 Clinicopathological features according to TLR4 and MyD88 expression
TLR4 MyD88 TLR4+MyD88
Clinicopathological factors
High
(n¼22)
Low
(n¼86) P-value
High
(n¼25)
Low
(n¼83) P-value
High
(n¼25)
Low
(n¼83) P-value
Age (years)
X65 10 38 0.915 11 37 0.9593 11 37 0.9593
o65 12 48 14 46 14 46
Sex
Male 14 48 0.5054 13 49 0.534 13 49 0.534
Female 8 38 12 34 12 34
Tumour site
Distal 20 71 0.3113 23 68 0.1972 23 68 0.1972
Proximal 2 15 2 15 2 15
Histology
Well 7 33 0.7685 4 36 0.0333 7 33 0.3139
Moderate 13 48 18 43 15 46
Poor/mucinous 2 5 3 4 3 4
Vascular invasion
Yes 13 34 0.0987 15 32 0.058 16 31 0.0186
No 9 42 10 51 9 52
Lymphatic invasion
Yes 18 61 0.3038 20 59 0.3779 18 61 0.8829
N o 42 5 52 4 72 2
Lymph node metastasis
Yes 13 51 0.9856 18 46 0.1392 16 48 0.5802
N o 92 5 73 7 93 5
Liver metastasis
Yes 11 11 0.0001 10 12 0.0054 12 10 0.0002
No 11 75 15 71 13 73
Peritoneal metastasis
Yes 4 5 0.0611 2 7 0.9452 3 6 0.4666
No 18 81 23 76 22 77
Stage
I, II 6 32 0.0197 7 31 0.0745 7 31 0.0036
III 5 39 7 35 5 37
IV 11 17 11 17 13 15
Abbreviations: TLR4¼Toll-like receptor 4; MyD88¼myeloid differentiation factor 88. Bold values indicate Po0.05.
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higher in TLR4 high-expression CRC than in TLR4 low-expression
CRC (Po0.05, Figure 1D). Similarly, significantly high levels of
TLR4 were detected in CRC with high MyD88 expression
(Po0.005, Figure 1D). Finally, the correlation between the
expression of TLR4 and MyD88 in CRC was confirmed using
Pearson’s correlation coefficient analysis (r¼0.33, Po0.05) and
Spearman’s correlation coefficient analysis (P¼0.003). In addi-
tion, 25 (23%) cancers showed a high-level combined expression of
TLR4/MyD88 (5þ: 12, 6þ:5 ,7þ: 7, and 8þ: 1) (Table 1).
Clinicopathological significance of TLR4 and MyD88
expression
The co-distribution of CRC with a high or low TLR4/MyD88
expression in relation to cancer and patient characteristics is
shown in Table 1. The high expression of TLR4 was significantly
associated with liver metastasis (P¼0.0001) and TNM stage
(P¼0.0197) and potentially related to peritoneal metastasis
(P¼0.0611). The high expression of MyD88 was significantly
associated with cancer histology (P¼0.0333) and liver metastasis
(P¼0.0054) and potentially related to TNM stage (P¼0.0745).
Furthermore, a high co-expression of TLR4/MyD88 was signifi-
cantly associated with vascular invasion (P¼0.0186), liver
metastasis (P¼0.0002), and TNM stage (P¼0.0036). In addition,
CRC with liver metastasis showed higher levels of TLR4
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Figure 2 Differences in immunostaining scores of TLR4 and MyD88 in
liver metastasis (þ) CRC (n¼22) and liver metastasis ( ) CRC (n¼86)
were analysed. The TLR4 (A), MyD88 (B), and combined TLR4/MyD88
expression (C) levels were significantly higher in liver metastasis (þ) CRC
than in liver metastasis ( ) CRC (P¼0.0015, P¼0.0035, P¼0.0001,
respectively).
Figure 1 Detection of TLR4 and MyD88 immunoreactivity in normal
colon tissues, adenoma, and CRC. (A) Normal colon mucosa (left) and
adenoma (right) showed no or weak immunoreactions for TLR4 (top)
and MyD88 (below), which was identified as negative expression in this
study. Original magnification,  200. (B) In contrast to the situation in
the normal and adenoma, strong immunostaining of TLR4, which was
localized in the membrane (top) or cytoplasm (below), was observed in
the cancer cells. Original magnification, right,  200; left,  400. (C) Strong
immunostaining of MyD88, which was localised in the cytoplasm, was
observed in the cancer cells. Original magnification, right,  200; left,
 400. (D) High expression of TLR4 was correlated with high expression
of MyD88 in CRC. CRC with a high expression of TLR4 (n¼22) showed
significantly high levels of MyD88 expression than did CRC with a low
expression of TLR4 (n¼86) (Po0.05). CRC with a high expression of
MyD88 (n¼25) showed significantly high levels of TLR4 expression than
did CRC with a low expression of MyD88 (n¼83) (Po0.005).
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(Figure 2A–C, P¼0.0015, P¼0.0035, P¼0.0001, respectively).
Clinicopathological parameters and patient survival
in CRC
At the 5-year follow-up, 53 patients had tumour recurrence (DFS
rate: 49%), and 46 patients had died (OS rate: 43%). In univariate
analysis, histology (DFS, P¼0.0322; OS, P¼0.0084), TNM stage
(DFS, Po0.0001; OS, P¼0.0001), vascular invasion (DFS,
Po0.0001; OS, P¼0.0001), lymphatic invasion (DFS, P¼0.001;
OS, P¼0.0121), lymph node metastasis (DFS, P¼0.0001; OS,
P¼0.0017), liver metastasis (DFS, Po0.0001; OS, Po0.0001), and
peritoneal metastasis (DFS, P¼0.0386; OS, P¼0.007) were
important factors associated with DFS and OS (Table 2). Patient
age, sex, and tumour location were not related to DFS or OS
(Table 2). Multivariate analysis was performed to identify
independent prognostic factors. In Table 3, models that include
all histopathological variables and tumour markers found to
have significant prognostic value in univariate analysis (Table 2)
are shown. In Table 3 modelsA and B, TNM stage was signifi-
cantly associated with DFS (A, P¼0.0026; B, P¼0.0043) and OS
(A, P¼0.0074; B, P¼0.0216), and the presence of liver metastasis
was significantly associated with DFS (A, P¼0.0373; B, P¼0.047)
(Table 3). In Table 3 model B, the presence of lymphatic invasion
was significantly associated with DFS (P¼0.0362), and histology
was significantly associated with OS (P¼0.0435) (Table 3).
TLR4 and MyD88 expression and patient survival in CRC
We assessed the influence of high expression of TLR4 and MyD88
in CRC on patient survival. Patients with a high TLR4 expression
had a worse DFS than did those with a low TLR4 expression (36 vs
55%, Figure 3A). However, a high expression of TLR4 did not
significantly influence DFS (log-rank P¼0.1177; Figure 3A). High
expression of MyD88 and high co-expression of TLR4/MyD88
were significantly related to poor DFS (log-rank P¼0.0029; log-
rank P¼0.0042, respectively, Figure 3C and E). Furthermore, high
expression of TLR4, MyD88, and co-expression TLR4/MyD88
were significantly associated with poor OS (log-rank P¼0.013;
log-rank P¼0.0001; log-rank P¼0.0001, respectively, Figures 3B,
D, and F).
In univariate analysis, high expression of TLR4 was not
significantly related to DFS (Table 2). High expression of MyD88
Table 3 Clinicopathological features, tumour markers, and patient survival (multivariate analysis)
Variable 5-Year DFS HR (95% CI) P-value 5-Year OS HR (95% CI) P-value
Model A
Histology (poor/moderate vs well) 1.31 (0.67–2.55) 0.4342 1.75 (0.8–3.81) 0.1619
TNM stage (III/IV vs I/II) 8.52 (2.11–24.33) 0.0026 8.17 (1.76–27.28) 0.0074
Vascular invasion (yes vs no) 1.32 (0.69–2.54) 0.4034 1.55 (0.77–3.11) 0.2169
Lymphatic invasion (yes vs no) 2.53 (0.96–6.67) 0.061 1.50 (0.69–3.83) 0.4004
Lymph node metastasis (yes vs no) 0.56 (0.21–1.53) 0.259 0.49 (0.15–1.5) 0.2058
Liver metastasis (yes vs no) 2.02 (1.04–3.92) 0.0373 1.68 (0.79–3.58) 0.1791
Peritoneal metastasis (yes vs no) 0.99 (0.43–2.31) 0.9897 1.23 (0.49–3.08) 0.655
TLR4 (high vs low) — — 1.39 (0.67–2.89) 0.381
MyD88 (high vs low) 2.01 (1.00–4.03) 0.0494 2.31 (1.09–4.89) 0.0279
Model B
Histology (poor/moderate vs well) 1.53 (0.81–2.89) 0.1873 2.11 (1.02–4.37) 0.0435
TNM stage (III/IV vs I/II) 7.17 (1.86–25.68) 0.0043 5.56 (1.87–21.68) 0.0216
Vascular invasion (yes vs no) 1.33 (0.69–2.56) 0.3887 1.35 (0.77–3.11) 0.2224
Lymphatic invasion (yes vs no) 2.85 (1.07–7.61) 0.0362 1.74 (0.67–4.5) 0.2522
Lymph node metastasis (yes vs no) 0.67 (0.25–1.75) 0.4071 0.67 (0.22–1.96) 0.4602
Liver metastasis (yes vs no) 1.97 (1.01–3.86) 0.047 1.83 (0.87–3.83) 0.1093
Peritoneal metastasis (yes vs no) 0.89 (0.38–2.11) 0.8065 1.21 (0.5–2.9) 0.6739
TLR4+MyD88 (X5+ vs o5+) 1.87 (0.97–3.59) 0.0625 2.11 (1.05–4.23) 0.0352
Abbreviations: DFS¼disease-free survival; HR¼hazard ratio; CI¼confidence interval; OS¼overall survival; TNM¼tumour, node, metastasis; TLR4¼Toll-like receptor 4;
MyD88¼myeloid differentiation factor 88. Bold values indicate Po0.05.
Table 2 Clinicopathological features, tumour markers, and patient survival (univariate analysis)
Variable 5-Year DFS HR (95% CI) P-value 5-Year OS HR (95% CI) P-value
Age (X65years vs o65 years) 0.84 (0.48–1.45) 0.5355 1.17 (0.65–2.08) 0.5934
Sex (male vs female) 0.95 (0.55–1.63) 0.8568 0.95 (0.53–1.71) 0.8781
Tumour site (distal vs proximal) 2.89 (1.16–8.97) 0.0656 3.17 (0.98–10.23) 0.0534
Histology (poor/moderate vs well) 1.95 (1.05–3.6) 0.0322 2.57 (1.27–5.19) 0.0084
TNM stage (III/IV vs I/II) 8.07 (3.2–20.33) o0.0001 6.26 (2.46–15.88) 0.0001
Vascular invasion (yes vs no) 3.28 (1.86–5.78) o0.0001 3.35 (1.82–6.16) 0.0001
Lymphatic invasion (yes vs no) 4.68 (1.86–11.79) 0.001 3 (1.27–7.09) 0.0121
Lymph node metastasis (yes vs no) 3.64 (1.87–7.09) 0.0001 3.07 (1.52–6.2) 0.0017
Liver metastasis (yes vs no) 5.04 (2.85–8.9) o0.0001 5.35 (2.94–9.74) o0.0001
Peritoneal metastasis (yes vs no) 2.32 (1.05–5.18) 0.0386 3.06 (1.35–6.91) 0.007
TLR4 (high vs low) 1.62 (0.87–2.99) 0.1213 2.17 (1.15–4.07) 0.015
MyD88 (high vs low) 2.33 (1.31–4.13) 0.0038 3.03 (1.67–5.48) 0.0002
TLR4+MyD88 (X5+ vs o 5+) 2.25 (1.27–3.99) 0.0053 2.97 (1.64–5.38) 0.0003
Abbreviations: DFS¼disease-free survival; HR¼hazard ratio; CI¼confidence interval; OS¼overall survival; TNM¼tumour, node, metastasis; TLR4¼Toll-like receptor 4;
MyD88¼myeloid differentiation factor 88. Bold values indicate Po0.05.
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P¼0.0038) and high co-expression of TLR4/MyD88 (HR: 2.25;
95% CI: 1.27–3.99; P¼0.0053; Table 2) were significantly related
to poor DFS. In addition, high expression of TLR4 (HR: 2.17; 95%
CI: 1.15–4.07; P¼0.015), MyD88 (HR: 3.03; 95% CI: 1.67–5.48;
P¼0.0002), and co-expression of TLR4/MyD88 (HR: 2.97; 95% CI:
1.64–5.38; P¼0.0003; Table 2) significantly influenced OS.
In multivariate analysis of Table 3 model A, high expression of
MyD88 was significantly associated with poor DFS (adjusted HR:
2.01; 95% CI: 1.00–4.03; P¼0.0494) and OS (adjusted HR: 2.31;
95% CI: 1.09–4.89; P¼0.0279) (Table 3). High co-expression of
TLR4/MyD88 was significantly associated with poor OS (adjusted
HR: 2.11; 95% CI: 1.05–4.23; P¼0.0352; Table 3 model B) and
potentially related to poor DFS (HR: 1.87; 95% CI: 0.97–3.59;
P¼0.0625; Table 3 model B). As the TNM stage includes
metastasis information, we excluded all metastasis factors from
Table 4 models and analysed survival significance of TLR4,
MyD88, and TLR4/MyD88. In Table 4 model A, multivariate
analysis showed that high expression of TLR4 was significantly
associated with poor OS (adjusted HR: 1.88; 95% CI: 0.99–3.55;
P¼0.0298; Table 4). In Table 4 model B, high expression of MyD88
was significantly associated with poor DFS and OS (adjusted
HR: 1.93; 95% CI: 1.01–3.67; P¼0.0441; adjusted HR: 2.25; 95%
CI: 1.17–4.33; P¼0.0112, respectively, Table 4). Table 4 model C
showed that high co-expression of TLR4/MyD88 was also
significantly associated with poor DFS (adjusted HR: 2.06; 95%
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Figure 3 Kaplan–Meier survival curves of DFS and OS in patients with CRC according to TLR4 and MyD88 expression. (A, B) High expression of TLR4
was potentially associated with poor DFS and significantly associated with poor OS (P¼0.013). (C, D) High expression of MyD88 was significantly
associated with poor DFS and OS (P¼0.0029, P¼0.0001, respectively). (E, F) High co-expression of TLR4þMyD88 was significantly associated with poor
DFS and OS (P¼0.0042, P¼0.0001, respectively).
Table 4 Clinicopathological features, tumour markers, and patient survival (multivariate analysis)
Variable 5-Year DFS HR (95% CI) P-value 5-Year OS HR (95% CI) P-value
Model A
TLR4 (high vs low) 1.31 (0.71–2.43) 0.3816 1.88 (0.99–3.55) 0.0298
Histology (poor/moderate vs well) 1.82 (0.98–3.37) 0.0572 2.52 (1.24–5.14) 0.0065
TNM stage (III/IV vs I/II) 5.8 (2.26–15.09) 0.0003 4.6 (1.72–12.01) 0.0013
Vascular invasion (yes vs no) 1.81 (1.01–3.25) 0.0448 2.23 (1.18–4.2) 0.019
Lymphatic invasion (yes vs no) 2.35 (0.91–6.07) 0.0752 1.518 (0.62–3.67) 0.4202
Model B
MyD88 (high vs low) 1.93 (1.01–3.67) 0.0441 2.25 (1.17–4.33) 0.0112
Histology (poor/moderate vs well) 1.54 (0.8–2.95) 0.1878 1.89 (0.9–3.99) 0.0679
TNM stage (III/IV vs I/II) 5.98 (2.28–15.68) 0.0003 4.52 (1.7–11.99) 0.0017
Vascular invasion (yes vs no) 1.61 (0.87–2.97) 0.122 2.08 (1.09–3.97) 0.0414
Lymphatic invasion (yes vs no) 2.27 (0.86–5.94) 0.0944 1.38 (0.55–3.45) 0.5922
Model C
TLR4+MyD88 (X5+ vs o 5+) 2.06 (1.11–3.82) 0.0216 2.4 (1.28–4.52) 0.0041
Histology (poor/moderate vs well) 1.74 (0.93–3.24) 0.0806 2.3 (1.13–4.69) 0.0155
TNM stage (III/IV vs I/II) 5.89 (2.24–15.45) 0.0003 4.48 (1.68–11.92) 0.0018
Vascular invasion (yes vs no) 1.53 (0.82–2.84) 0.173 1.87 (0.96–3.62) 0.0918
Lymphatic invasion (yes vs no) 2.52 (0.97–6.56) 0.0577 1.58 (0.64–3.92) 0.3742
Abbreviations: DFS¼disease-free survival; HR¼hazard ratio; CI¼confidence interval; OS¼overall survival; TNM¼tumour, node, metastasis; TLR4¼Toll-like receptor 4;
MyD88¼myeloid differentiation factor 88. Bold values indicate Po0.05.
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sCI: 1.11–3.82; P¼0.0216) and OS (adjusted HR: 2.4; 95% CI: 1.28–
4.52; P¼0.0041) (Table 4).
DISCUSSION
It was recently reported that TLR4/MyD88 signalling drives
tumour growth in numerous organs (Rakoff-Nahoum and
Medzhitov, 2009). Toll-like receptor 4 and other TLRs have been
detected in many murine and human cancer cell lines, including
laryngeal, lung, breast, gastric, colon, prostate cancer, and
melanoma (Huang et al, 2008). Silencing TLR4 signalling in
tumour cells results in reduced tumour formation (Huang et al,
2005), and the inhibition of tumour-cell apoptosis by TLR-
signalling was also observed in ovarian, lung cancer, and myeloma
cells (Jego et al, 2006; Kelly et al, 2006; He et al, 2007). In addition,
it was shown that MyD88 is crucial for the promotion of
diethylnitrosamine-induced hepatocellular tumours (Naugler
et al, 2007). Recently, MyD88 has also been shown to be crucial
for tumour promotion in models of spontaneous (Apc
min/þ) and
carcinogen-induced (azoxymethane) intestinal tumourigenesis
(Rakoff-Nahoum and Medzhitov, 2007). In addition, MyD88 is a
positive regulator of chemically induced tumours of both the skin
and connective tissue (Swann et al, 2008). In this study, we
observed that TLR4/MyD88 signalling was frequently overex-
pressed in CRC compared with normal mucosae and adenomas.
A correlation between TLR4 and MyD88 expression was detected.
These findings indicated that TLR4/MyD88 signalling in tumour
cells itself has important roles as oncogenic factors in CRC.
It is not yet clear whether TLR4 and MyD88 are involved in
tumour initiation (Rakoff-Nahoum and Medzhitov, 2009). In
humans, chronic infection and inflammation are considered to
be two of the most important factors contributing to tumourigen-
esis and tumour progression (Balkwill and Coussens, 2004). Toll-
like receptor signalling may have an important role in numerous
cancers, including gastric, ovarian, lung, pancreatic, liver, and
colon cancer, which have been shown to be associated with local
chronic inflammation (Kelly et al, 2006; Fukata et al, 2007; He et al,
2007; Naugler et al, 2007; Schwartz et al, 2009). Upregulated
stimulation of TLRs could lead to damage and mutation of
genomic DNA and aberrant chromosomal translocation (Rakoff-
Nahoum and Medzhitov, 2009). Toll-like receptor 4 signalling
activation seems to promote the development of colitis-associated
cancer by mechanisms including enhanced Cox-2 expression and
increased EGFR signalling (Fukata et al, 2007). Excluding colitis-
associated cancers, commensal bacteria have also been implicated
in the development of sporadic CRC (Hope et al, 2005) and may
promote CRC by inducing chromosomal instability (Wang and
Huycke, 2007). Our findings suggest that TLR4/MyD88 signalling
contributes to CRC tumourigenesis not just in colitis-associated
cancer but also in sporadic CRC.
The molecular pathway that links inflammation to the acquisi-
tion of metastatic capacity during tumour progression has been
investigated (Kim et al, 2009). By activating TLR2:TLR6 complexes
and inducing TNF-a secretion in myeloid cells, versican strongly
enhances Lewis lung carcinoma metastatic growth (Kim et al,
2009). Activation of tumour cell TLR can enhance the invasion and
metastasis of tumour cells by regulating metalloproteinases
(MMPs) and integrins (Wang et al, 2003; Huang et al, 2008). The
highly invasive MDA-MB-231 breast cancer cell line expresses
TLR9, which promotes tumour cell invasion by increasing the
activity of MMP-13 (Merrell et al, 2006). Toll-like receptor 4
signalling in colon cancer cells is involved in tumour immune
escape, accompanied by apoptosis resistance and the preferential
induction of immunosuppressive factors and chemokines, such as
TGF-b, NO, IL-8, MCP-1, and MMP-9, resulting in tumourigenesis
and the promotion of tumour metastasis (Cianchi et al, 2004;
Molteni et al, 2006; Wang et al, 2003, Lee and Lim, 2007). Earl et al
(2009) reported that silencing of TLR4 in tumour cells reduces the
metastatic tumour burden in steatotic livers. Recently, Killeen et al
(2009) suggested that bacterial endotoxins directly promote
tumour cell adhesion and invasion through upregulation of
urokinase plasminogen activator and the urokinase plasminogen
activator receptor through TLR-4-dependent activation of NF-kB.
Our study showed that TLR4/MyD88 overexpression was fre-
quently detected in CRC with liver metastasis, and TLR4/MyD88
levels were significantly higher in these CRCs. Our findings suggest
that TLR4/MyD88 signalling promotes CRC progression by
contributing to liver metastasis.
Silencing TLR4/MyD88 signalling in tumour cells not only
results in reduced tumour formation but also leads to prolonged
survival after subcutaneous tumour injection in mice (Huang et al,
2005; Rakoff-Nahoum and Medzhitov, 2007). These effects suggest
that blocking TLR4/MyD88 signalling would provide a survival
benefit. However, the association between TLR signalling and
cancer mortality has not been well investigated in clinical samples.
Our results clearly demonstrated that overexpression of TLR4/
MyD88 was an independent and significant prognostic factor for
5-year DFS and OS. This is the first study to show an association
between TLR4/MyD88 expression and CRC patient survival.
Previous studies reported that elevation of the downstream
signals of the TLR4/MyD88 pathway, such as Cox-2 and NF-kB,
was related to CRC patient survival. We see that TLR4/MyD88
regulates the expression of Cox-2, which shows its important
role in many aspects of tumour growth (Fukata and Abreu,
2008; Rakoff-Nahoum and Medzhitov, 2009). Cyclooxygenase-2 is
also considered to have an important role in colorectal carcino-
genesis. Recently, Ogino et al (2008) reported that Cox-2
overexpression is associated with worse survival among colon
cancer patients. Nuclear factor-kB is an end point of the TLR4/
MyD88 signalling pathway. Numerous lines of evidence that link
NF-kB activation to cancer development have been reported.
Constitutive NF-kB activation is found in most cancer cell lines
and in numerous types of tumour tissues (Shishodia and Aggarwal
2004). Scartozzi et al (2007) reported that NF-kB nuclear
expression predicts response and survival in irinotecan-refractory
metastatic CRC treated with cetuximab–irinotecan therapy. These
findings suggested that the tumour cell TLR4/MyD88 signalling
pathway has a crucial role in CRC patient prognosis and that
blocking this pathway could provide great benefits for patients
with CRC.
Recently, several approaches to the treatment of TLR4-mediated
diseases have been investigated. Rapamycin may abrogate TLR-
triggered colon cancer cell-immune escape and invasion by
downregulating TLR4 expression and inhibiting the TLR4-
activated NF-kB pathway (Sun et al, 2008). Interestingly, TAK-
242, a small-molecule antisepsis agent, has been demonstrated to
be a selective inhibitor of TLR4 signalling (Kawamoto et al, 2008).
Our study suggests that it is necessary to investigate the usefulness
of TAK-242 in CRC therapy.
Our study profiled the status of TLR4 and MyD88 in CRC and
indicated that this signalling pathway was associated with an
increased risk of liver metastasis and worse survival. This study,
for the first time, showed the clinicopathological significance of
tumour cell self-TLR4/MyD88 expression in CRC. These findings
suggested the novel therapeutic possibility of targeting tumour cell
TLR4/Myd88 signals in CRC.
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